Are DOGE layoffs set to resume?
ResMed Inc . (NYSE:RMD), a $37 billion market cap healthcare company, saw Chief Executive Officer Michael J. Farrell recently sell a significant portion of his holdings, according to a June 9 SEC filing. Farrell sold 8,009 shares of ResMed common stock at a weighted average price of $251.21 per share, totaling approximately $2.01 million. This transaction was conducted under a pre-established Rule 10b5-1 trading plan. According to InvestingPro data, ResMed maintains a "Great" financial health score of 3.45/5, suggesting strong operational performance.
Additionally, Farrell exercised options to acquire 8,009 shares at a price of $101.64 per share, a move that resulted in a total transaction value of $814,034. Following these transactions, Farrell’s direct ownership in ResMed stands at 455,503 shares, while indirect holdings through the Lisette and Michael Farrell Family Trust amount to 2,090 shares.
These transactions are part of Farrell’s ongoing management of his investment in ResMed, a global leader in connected health solutions.
In other recent news, ResMed’s third-quarter fiscal year 2025 results have drawn attention from various analysts. Citi analysts raised their price target for ResMed to AUD45.00, maintaining a Buy rating, following the company’s earnings that met expectations and prompted an increase in projected earnings per share for fiscal years 2025 to 2027. UBS also reaffirmed a Buy rating with a price target of $285.00, highlighting the potential impact of Apnimed’s new obstructive sleep apnea treatment on ResMed’s market. Meanwhile, Stifel analysts maintained a Hold rating with a $240.00 target, noting mixed results in device and mask sales, and expressing concerns about GLP-1 medications potentially affecting future growth.
RBC Capital Markets adjusted their price target for ResMed to $255.00, maintaining a Sector Perform rating, after the company’s earnings and revenue growth aligned with market expectations. Notably, ResMed announced that its products would largely remain exempt from U.S. import tariffs, which RBC Capital views as a positive development. Analysts from Citi and RBC Capital both emphasized ResMed’s strong free cash flow and robust growth outlook. However, Stifel expressed medium-term concerns due to potential challenges associated with GLP-1 medications. These developments reflect a diverse range of analyst perspectives on ResMed’s current market position and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.